drugset / Trial / NCT05579691

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

NCT05579691 ↗

Phase 2 Completed 28 enrolled Larimar Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).

Timeline

Start
2022-09-21
Primary completion
2023-12-04
Completion
2023-12-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nomlabofusp Protein / enzyme biologic 25 mg Subcutaneous
Subject Nomlabofusp Protein / enzyme biologic 50 mg Subcutaneous

Indications